Rare disease drugmaker files for approval despite objections from FDA on adequate trial data

Zachary Brennan

Senior Editor

Another small biotech attacking a super-rare disease is leveraging a patient community and very limited clinical data to try to win an FDA approval. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare disease drugmaker files for approval despite objections from FDA on adequate trial data

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

What will pharma's share buyback shopping spree mean for M&A?

Trump 2.0 blog: Wayback Machine is insufficient for US health data, judge says

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Biohaven lands priority review on second-chance application for neurodegenerative drug

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Rare dis­ease drug­mak­er files for ap­proval de­spite ob­jec­tions from FDA on ad­e­quate tri­al da­ta

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Rare disease drugmaker files for approval despite objections from FDA on adequate trial data